Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia

Establishment of Indications on the Basis of Individual Risk Stratification by Prof. Dr. med. Dr. h. c. Axel R. Zander et al. in volume 39/2008

**Statement Was Not Sufficiently Supported**

Zander et al. conclude in their article that in patients with acute myeloid leukemia who are in second remission the result of transplantation from unrelated donors are "equivalent" to those from sibling donors. This statement is not supported by the literature cited by Zander et al. The publication cited in support (1) does not mention any comparison of related and unrelated donors. The article is an evaluation of a registry of patients with promyelocytic leukemia who had either received autologous transplants or a transplant from an HLA identical sibling donor. It does thus not contradict our conclusion (2) in the IQWiG (Institute for Quality and Efficiency in Health Care-Home) report. The most suitable instruments for comparing therapeutic alternatives are prospective, controlled studies that ensure identical structures. "Genetically randomized" studies have shown that studies that are fairly close approximations of this design are possible even in stem cell transplantation. One such study was conducted, for example, which compared transplantation with dose reduced conditioning versus chemotherapy (3). The study showed a clear advantage of dose-reduced conditioning in leukemia-free survival. In addition to many other studies of a similar design, it confirmed our approach (2) that it is entirely possible to evaluate stem cell transplantation in a methodologically valid manner and with relevance to health care delivery.

**REFERENCES**

1. Sanz MA et al.: Acute Leukemia Working Party (ALWP) of European Cooperative Group for Blood and Marrow Transplantation (EBMT). Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2007; 39: 461–9.

2. IQWiG: Stammzelltransplantation bei den Indikationen Akute lymphatische Leukämie (ALL) und Akute myeloische Leukämie (AML) bei Erwachsenen. Abschlussbericht N05-G03A. Köln: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); März 2007.

3. Mohy M et al.: Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a ‘donor’ versus ‘no donor’ comparison. Leukemia 2008; in print.

4. Zander AR, Bacher U, Finke J: Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia — Establishment of Indications on the Basis of Individual Risk Stratification. Dtsch Arztebl Int 2008; 105(39): 663-9.

**In Reply:**

Herrmann-Frank et al. doubt that transplantation of HLA identical unrelated donors is equivalent to sibling donor transplantation. Since for most AML patients no HLA identical related donor is available, but an HLA identical unrelated donor may be found, this is indeed important. The study by Mohy et al that is cited by Herrmann-Frank, on the comparison of dose reduced conditioning if a HLA identical family donor is available with standard or high dose chemotherapy if none is available shows unequivocally the superiority of family donor transplantation vis-à-vis other, non-transplantation, strategies in AML. Several larger studies confirmed the equivalence of HLA identical unrelated donor transplantation versus family donor transplantation in AML. An analysis of HLA identical unrelated donor transplantation versus family donor transplantation, which included 175 AML patients, cytomegaly serostatus and a severe donor-host reaction were relevant for survival, whereas the type of transplantation was not (1). Comparing the results of HLA compatible unrelated donor and family donor transplantations in 368 AML patients in a study showed that the donor type was not a significant prognostic factor for survival after allogeneic stem cell transplantation in older patients with standard and high risk AML (2). Patients with AML who would benefit from allogeneic stem cell transplantation but who have no family donor should therefore receive a transplant from an unrelated donor. Further evaluation of both transplantation methods is, however, desirable.

**REFERENCES**

1. Yakoub-Agha I et al.: Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006; 24: 5695–702.

2. Schetelig J et al.: Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol 2008; 26: 5183–91.

3. Zander AR, Bacher U, Finke J: Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia — Establishment of Indications on the Basis of Individual Risk Stratification. Dtsch Arztebl Int 2008; 105(39): 663-9.

**Conflict of interest statement**

The authors of both the letter and the reply declare that no conflict of interest exists according to the guidelines of the International Committee of Medical Journal Editors.